- Postmenopausal osteoporosis
- Glucocorticoid-induced osteoporosis
- Primary or hypogonadal osteoporosis men
GEMFRAC
MRP | : |
|
Price | : | ₹3,100.00 |
You Save | : | ₹650.00 (17.33%) |
1 vial(s) of 2.4ml
Gemfrac 600mcg injection contains an active component called teriparatide, which belongs to a group of parathyroid hormone (PTH) drugs. It is used to treat osteoporosis in adults. It is a condition marked by weakened bones, heightening the likelihood of fractures. It strengthens the bone and promotes the creation of new bone tissue in individuals. It is used to postmenopausal women with osteoporosis, increase bone mass in primary or hypogonadal osteoporosis men, and also to treat both men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
Inform your doctor if you are allergic to teriparatide or any of its ingredients. Consult your doctor if you have a serious kidney disorder, bone cancer, or bone disorder or if you have recently undergone radiation therapy for your bones. Inform your doctor about your prescribed and non-prescribed medicine. Consult your doctor if you are planning to get pregnant or think you may be pregnant or while you are breastfeeding. The safety and effectiveness of the drug have not been established in children or pediatric patients.